



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/470748/2021

European Medicines Agency decision P/0352/2021

of 8 September 2021

on the granting of a product specific waiver for florbetaben (18F) (Neuraceq), (EMEA-001090-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0352/2021

of 8 September 2021

on the granting of a product specific waiver for florbetaben (18F) (Neuraceq), (EMA-001090-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Life Molecular Imaging GmbH on 21 April 2021 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 July 2021 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for florbetaben (18F) (Neuraceq), solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 - Berlin, Germany.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

EMA/PDCO/268876/2021
Amsterdam, 23 July 2021

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001090-PIP02-21

Scope of the application

Active substance(s):

Florbetaben (18F)

Invented name:

Neuraceq

Condition(s):

Diagnosis of cardiac amyloidosis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Life Molecular Imaging GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Life Molecular Imaging GmbH submitted to the European Medicines Agency on 19 April 2021 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 25 May 2021.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Diagnosis of cardiac amyloidosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- solution for injection, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Diagnosis of β -amyloidosis

Authorised indication(s):

- This medicinal product is for diagnostic use only. Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β -amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan see sections 4.4 and 5.1.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Intravenous use